Anxiolytics
Also known as: antianxiety drugs, anti-anxiety medications
Anxiolytics are medications used to reduce anxiety. The class includes benzodiazepines, buspirone, certain antidepressants, and sedating antihistamines, and it overlaps closely with sedatives and hypnotics, which are often the same drugs at higher doses.
Anxiolytic, sedative, and hypnotic effects sit on a dose-related continuum for many central nervous system depressants. A low dose relieves anxiety, a higher dose sedates, and a higher dose still induces sleep. That is why pharmacy references group these agents together even though their clinical indications differ.
Benzodiazepines — alprazolam, lorazepam, diazepam, clonazepam — bind an allosteric site on the GABA-A receptor and increase the frequency of chloride channel opening, enhancing inhibitory neurotransmission. They act quickly, which makes them useful for acute anxiety, but they are Schedule IV controlled substances with tolerance, dependence, and withdrawal risk, and they carry serious additive respiratory depression risk with opioids and alcohol. Flumazenil is the specific reversal agent. Barbiturates act at the same receptor complex but increase channel opening duration and have a much narrower margin of safety.
Non-benzodiazepine options avoid those liabilities. Buspirone is a serotonin 5-HT1A partial agonist that is not sedating and does not produce dependence, but takes weeks to work, so it suits chronic rather than acute anxiety. SSRIs and SNRIs are standard long-term therapy for generalized anxiety, panic, and social anxiety disorders. Hydroxyzine, an antihistamine, is used for short-term anxiety without controlled substance status, and beta blockers such as propranolol blunt the physical symptoms of situational anxiety. The related hypnotics include the Z-drugs zolpidem, zaleplon, and eszopiclone, which act at GABA-A but are more selective for sedation.
The PTCE covers anxiolytics, sedatives, and hypnotics among drugs of the nervous system, expecting technicians to know brand and generic pairings, controlled substance schedules, and common auxiliary warnings. USMLE Step 1 addresses the pharmacology and its role in behavioral science, and AP Psychology includes anxiolytics in its treatment of psychological disorders unit.
Key takeaways
- Anxiolytic, sedative, and hypnotic effects often represent increasing doses of the same central nervous system depressants.
- Benzodiazepines enhance GABA-A signaling by increasing chloride channel opening frequency and are Schedule IV controlled substances.
- Barbiturates increase channel opening duration and have a narrower therapeutic margin than benzodiazepines.
- Buspirone is a non-sedating 5-HT1A partial agonist with delayed onset and no dependence risk.
- SSRIs and SNRIs are standard long-term therapy for chronic anxiety disorders, while hydroxyzine and beta blockers offer non-controlled alternatives.